Alecensa 150 mg, 224 capsules (Alectinib 150 mg) by Roche.
Indications: First-line and post-crizotinib treatment of adults with ALK-positive advanced non-small cell lung cancer (NSCLC); adjuvant treatment after resection.
Administration: Oral: 600 mg (4 capsules) twice daily with food, as prescribed by an oncologist.
Storage: Store below 25–30 °C in the original package. Keep out of the sight and reach of children.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Roche |
| Active ingredient | Alectinib 150 mg (as hydrochloride) per capsule — ALK tyrosine kinase inhibitor. |
| Strength & pack | 224 hard capsules. |
| Form | Hard capsules |
| Storage | Store below 25–30 °C in the original package. Keep out of the sight and reach of children. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |